Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Silence Therapeutics plc (SLN)

Silence Therapeutics prices $175 million share offering at $13.50 per ADS

Neutral Impact 3 of 5 financing Written later

Silence Therapeutics plc agreed on August 11, 2026 to sell 12,962,963 American Depositary Shares at $13.50 each in an underwritten public offering, with expected gross proceeds of about $175 million, up from the approximately $150 million announced on August 10. The company expects net proceeds of about $164.0 million, or about $188.7 million if underwriters fully exercise their option, and the offering is expected to close on August 13, 2026, which would add new shares for existing shareholders.

Key points

  • Offering of 12,962,963 ADSs at $13.50 per ADS, with underwriters buying at $12.69 per ADS
  • Expected net proceeds of about $164.0 million, or about $188.7 million with full exercise of the 30-day option for 1,944,444 additional ADSs
  • Joint book-running managers are Jefferies LLC and Morgan Stanley & Co. LLC; closing expected on or about August 13, 2026

The filing

CompanySilence Therapeutics plc (SLN)
Form8-K, current report
Filed with the SECAug 12, 2026, 5:23 PM ET
Accession number0001193125-26-347196

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.